Spin-Off Into a Crash: Agilent's Impossible First Year

On November 18, 1999, Agilent Technologies rang the opening bell at the New York Stock Exchange under the ticker symbol "A." It was one of the largest initial public offerings in Silicon Valley history, a $2.1 billion debut that valued the newly independent company at roughly $8 billion. The spin-off from Hewlett-Packard had been meticulously planned for over a year. Ned Barnholt, a 30-year HP veteran, took the helm as CEO. The mood was triumphant. Agilent inherited HP's crown jewels: electronic test and measurement, chemical analysis, and medical products — businesses built on six decades of innovation dating back to a Palo Alto garage.

Six months later, the telecommunications industry — Agilent's single largest customer — effectively stopped buying.

The Bubble Bursts

The dot-com collapse didn't arrive gradually. In the spring of 2000, venture capital dried up, internet startups folded by the week, and the telecom carriers that had been building out fiber-optic networks at a frenetic pace suddenly froze capital budgets. Orders for Agilent's network analyzers, signal generators, and oscilloscopes — the workhorses of that build-out — vanished almost overnight. Revenue in the electronic measurement division, which accounted for more than half the company's sales, fell off a cliff.

Barnholt later described the period as "a baptism by fire." The company's stock, which had soared after the IPO, tumbled in lockstep with the Nasdaq. Investors who had celebrated the spin-off as a masterstroke of corporate strategy now questioned whether a standalone measurement company could survive without HP's diversified cash flows. Internally, the euphoria of independence curdled into anxiety.

Cutting to Survive

The response was swift and painful. Within months, Agilent announced the first of several workforce reductions. Thousands of employees — many of them longtime HP loyalists who had chosen Agilent over the computing and printing side — were let go. Non-essential projects were canceled. Travel budgets were frozen. Supply chains were compressed. The company applied microscopic scrutiny to every expense, a discipline forged in the HP Way's emphasis on fiscal responsibility but now exercised with desperate intensity.

Yet Barnholt drew a hard line at research and development. Despite the revenue free-fall, Agilent protected its R&D budget, particularly in the chemical analysis and life sciences segments. The logic was cold-blooded: cutting R&D would save money today but guarantee obsolescence tomorrow. The telecommunications bust was cyclical; the demand for drug discovery, environmental testing, and food safety was structural. Agilent's gas chromatographs, liquid chromatographs, and mass spectrometers kept selling into pharmaceutical labs and regulatory agencies even as the telecom lines went silent.

The Pivot That Saved the Company

The crisis forced a strategic clarity that might have taken years to achieve in calmer times. Agilent's leadership realized that the electronic measurement business, while prestigious, was dangerously exposed to a single industry's boom-bust cycle. The chemical analysis and life sciences businesses, by contrast, served markets driven by regulation, public health, and scientific progress — demand that persisted through recessions.

This insight accelerated two major divestitures. In 2001, Agilent sold its medical products group — patient monitors, defibrillators, ultrasound — to Philips for $1.7 billion. The deal brought a cash infusion at the worst possible moment and removed a business with distinct regulatory and sales cycles. Four years later, the semiconductor products group was spun off into Avago Technologies, shedding another cyclical, capital-intensive operation. Each divestiture sharpened Agilent's focus on its core: precision measurement for science and industry.

A Culture Forged in Crisis

The dot-com bust did more than reshape the portfolio; it forged Agilent's identity. Employees who stayed described a palpable shift — a shared sense that they were no longer a division of a giant but a company fighting for its life. Town halls became candid; leadership acknowledged the severity of the downturn without sugarcoating. The transparency, a hallmark of the HP Way, built trust. When the economy eventually recovered, Agilent emerged leaner, more focused, and with a product pipeline intact because it had refused to mortgage the future for the present.

By 2003, revenue had stabilized. The acquisitions of Varian in 2010 and Dako in 2012 — transformative moves that established leadership in atomic spectroscopy and cancer diagnostics — were only possible because the company had survived its first crucible with its balance sheet and its R&D engine intact. The final piece fell into place in 2014, when the remaining electronic measurement business was spun off into Keysight Technologies, completing Agilent's transformation into a pure-play life sciences and diagnostics company.

The IPO banner that hung at the NYSE in November 1999 was taken down long ago. But the lesson of that first year — that focus beats diversification when the world turns upside down — remains encoded in Agilent's strategy. The company that rang the bell as a diversified measurement giant walked away, a year later, as a survivor with a clear mission. The rest was just execution.

This is one episode in a much longer story. For the full account of the history of Agilent Technologies, read “A History of Agilent Technologies” by Anthony D. Williams on MixCache.com.